{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:24:24Z","timestamp":1790918664171,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.clinthera.2006.08.002","type":"journal-article","created":{"date-parts":[[2006,9,19]],"date-time":"2006-09-19T15:16:16Z","timestamp":1158678976000},"page":"1144-1154","source":"Crossref","is-referenced-by-count":38,"title":["Patterns of Dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: A retrospective data analysis in Germany"],"prefix":"10.1016","volume":"28","author":[{"given":"Reinhard","family":"Sittl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Nuijten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Poulsen Nautrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.08.002_bib1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1185\/030079905X53315","article-title":"Transdermal buprenorphine in clinical practice\u2014a post-marketing surveillance study in 13,179 patients","volume":"21","author":"Griessinger","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2006.08.002_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.12968\/ijpn.2000.6.4.8929","article-title":"Issues in effective pain control. 2: From assessment to management","volume":"6","author":"Davies","year":"2000","journal-title":"Intj Palliat Nurs"},{"key":"10.1016\/j.clinthera.2006.08.002_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejpain.2005.02.006","article-title":"Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?","volume":"10","author":"Mercadante","year":"2006","journal-title":"Eur J Pain"},{"key":"10.1016\/j.clinthera.2006.08.002_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0885-3924(95)00162-X","article-title":"Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: Short- and long-term experiences in a prospective study of 39 patients","volume":"11","author":"Korte","year":"1996","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2006.08.002_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1191\/026921601678320296","article-title":"Transdermal fentanyl for the management of cancer pain: A survey of 1005 patients","volume":"15","author":"Radbruch","year":"2001","journal-title":"Palliat Med"},{"key":"10.1016\/j.clinthera.2006.08.002_bib6","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1213\/01.ANE.0000152191.29311.9B","article-title":"Age-dependent opioid escalation in chronic pain patients","volume":"100","author":"Buntin-Mushock","year":"2005","journal-title":"Anesth Analg"},{"key":"10.1016\/j.clinthera.2006.08.002_bib7","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.clinthera.2005.06.024","article-title":"Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: Results of a retrospective cohort study","volume":"27","author":"Sittl","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2006.08.002_bib8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0092-8674(02)00666-9","article-title":"Opioid tolerance-in search of the Holy Grail","volume":"108","author":"Kieffer","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2006.08.002_bib9","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1213\/01.ANE.0000160588.32007.AD","article-title":"The role of opioid receptor internalization and beta-arrestins in the development of opioid tolerance","volume":"101","author":"Zuo","year":"2005","journal-title":"Anesth Analg"},{"key":"10.1016\/j.clinthera.2006.08.002_bib10","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0022-3565(24)35398-4","article-title":"Ligand-induced changes in surface mu-opioid receptor number: Relationship to G protein activation?","volume":"292","author":"Zaki","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2006.08.002_bib11","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G","article-title":"Opioid rotation for cancer pain: Rationale and clinical aspects","volume":"86","author":"Mercadante","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2006.08.002_bib12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0304-3959(01)00465-1","article-title":"Pitfalls of opioid rotation: Substituting another opioid for methadone in patients with cancer pain","volume":"96","author":"Moryl","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2006.08.002_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1054\/jpai.2001.25352","article-title":"Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain","volume":"2","author":"Milligan","year":"2001","journal-title":"J Pain"},{"key":"10.1016\/j.clinthera.2006.08.002_bib14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1526-5900(03)00632-1","article-title":"Long-term management of noncancer pain with transdermal therapeutic system-fentanyl","volume":"4","author":"Mystakidou","year":"2003","journal-title":"J Pain"},{"key":"10.1016\/j.clinthera.2006.08.002_bib15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ijc.11416","article-title":"Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl","volume":"107","author":"Mystakidou","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clinthera.2006.08.002_bib16","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.clinthera.2006.06.012","article-title":"Long-term management of chronic pain with transdermal buprenorphine. A mul ticenter, open-label, follow-up study in patients from three short-term clinical trials","volume":"28","author":"Likar","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2006.08.002_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0885-3924(92)90116-Y","article-title":"Long-term oral opioid therapy in patients with chronic nonmalignant pain","volume":"7","author":"Zenz","year":"1992","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2006.08.002_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pain.2005.06.030","article-title":"Different profiles of buprenorphineinduced analgesia and antihyperal gesia in a human pain model","volume":"118","author":"Koppert","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2006.08.002_bib19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CPP40130","article-title":"Use of the Mediplus patient database in healthcare research","volume":"40","author":"Dietlein","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.08.002_bib20","series-title":"ICH Topic E6","article-title":"International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice","author":"European Agency for the Evaluation of Medicinal Products","year":"2002"},{"key":"10.1016\/j.clinthera.2006.08.002_bib21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clinthera.2005.02.012","article-title":"Equipotent doses of transdermal fentanyl and transdermal buprenor phine in patients with cancer and noncancer pain: Results of a retrospective cohort study","volume":"27","author":"Sittl","year":"2005","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2006.08.002_bib22","series-title":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision","year":"2004"},{"key":"10.1016\/j.clinthera.2006.08.002_bib23","series-title":"Transtec (transdermal buprenorphine)","year":"2003"},{"key":"10.1016\/j.clinthera.2006.08.002_bib24","series-title":"Durogesic (transdermal fentanyl)","year":"2001"},{"key":"10.1016\/j.clinthera.2006.08.002_bib25","author":"European Pharmaceutical Marketing Research Association"},{"key":"10.1016\/j.clinthera.2006.08.002_bib26","series-title":"Cancer pain relief and palliative care","author":"World Health Organization Guidelines","year":"1990"},{"key":"10.1016\/j.clinthera.2006.08.002_bib27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.18553\/jmcp.2003.9.3.223","article-title":"Patient-reported utilization patterns of fentanyl transdermal sys tem and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain","volume":"9","author":"Ackerman","year":"2003","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.clinthera.2006.08.002_bib28","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0885-3924(97)00361-8","article-title":"Long-term treatment of cancer pain with transdermal fentanyl","volume":"15","author":"Donner","year":"1998","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2006.08.002_bib29","series-title":"Statistical Methods in Medical Research","author":"Armitage","year":"1994"},{"key":"10.1016\/j.clinthera.2006.08.002_bib30","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/pds.1122","article-title":"Patterns of prescription of four major antipsychotics: A retro spective study based on medical records of psychiatric inpatients","volume":"14","author":"Gasquet","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2006.08.002_bib31","doi-asserted-by":"crossref","first-page":"9097","DOI":"10.1046\/j.1524-4733.2003.00242.x","article-title":"A checklist for retrospective database studies-report of the ISPOR Task Force on Retrospective Databases","volume":"6","author":"Motheral","year":"2003","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2006.08.002_bib32","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00482-005-0432-9","article-title":"Long-term efficacy of opioid medication in patients with chronic non-cancerassociated pain. Results of a survey 5 years after onset of medical treatment","volume":"19","author":"Maier","year":"2005","journal-title":"Schmerz"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T22:44:28Z","timestamp":1736549068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806001822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0149291806001822"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.08.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}